Internal Medicine, Endocrinology, Diabetes, & Metabolism · Shreveport, LA
NPI
1053504662
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
2551 Greenwood Rd Ste 411
Shreveport, LA, 71103
Phone (318) 212-8624
Groups this clinician bills Medicare through
Medicare paid, 2024
$85K
2,659 services
Medicare patients, 2024
273
Average age 72
Drug cost, 2024
$3.8M
6,591 prescriptions
Company payments, 2025
$3,065
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michelle A Chico was code 99214 (office e&m - established), 585 times for 236 patients. In total Michelle A Chico billed 2,659 services in 16 codes, and Medicare paid $85K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 585 | 236 | $84.01 | $49K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 366 | 176 | $11.40 | $4,173 |
| 95251 Test - Miscellaneous | Office | 350 | 119 | $24.09 | $8,433 |
| 99215 Office E&M - Established | Office | 77 | 57 | $118.68 | $9,138 |
| 99211 Office E&M - Established | Office | 44 | 28 | $15.53 | $683 |
| 99204 Office E&M - New | Office | 42 | 42 | $114.93 | $4,827 |
| 99213 Office E&M - Established | Office | 24 | 19 | $64.14 | $1,539 |
| 95250 Test - Miscellaneous | Office | 20 | 20 | $101.88 | $2,038 |
By year: 2022 $78K for 917 services; 2023 $99K for 5,579 services; 2024 $85K for 2,659 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michelle A Chico prescribed most often to Medicare patients was Rosuvastatin Calcium, with 486 prescriptions and refills. In total Michelle A Chico wrote 6,591 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rosuvastatin Calcium Generic | 486 | 1,148 | 135 | $7,546 |
| Atorvastatin Calcium Generic | 479 | 1,043 | 123 | $4,159 |
| Jardiance Empagliflozin | 465 | 770 | 98 | $440K |
| Levothyroxine Sodium Generic | 436 | 915 | 106 | $4,322 |
| Mounjaro Tirzepatide | 401 | 437 | 63 | $444K |
| Ozempic Semaglutide | 371 | 447 | 79 | $414K |
| Trulicity Dulaglutide | 312 | 398 | 74 | $377K |
| Ezetimibe Generic | 284 | 631 | 77 | $5,816 |
| Tresiba Flextouch U-100 Insulin Degludec | 261 | 367 | 82 | $224K |
| Tresiba Flextouch U-200 Insulin Degludec | 224 | 329 | 51 | $362K |
| Farxiga Dapagliflozin Propanediol | 210 | 382 | 46 | $213K |
| Kerendia Finerenone | 184 | 318 | 36 | $202K |
| Januvia Sitagliptin Phosphate | 164 | 306 | 29 | $164K |
| Synthroid Levothyroxine Sodium | 163 | 355 | 40 | $14K |
| Trijardy Xr Empaglifloz/Linaglip/Metformin | 157 | 209 | 24 | $115K |
Brand drugs: 4,343 claims; generic drugs: 1,920 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michelle A Chico $3,065 ($3,065 in general payments such as food, travel and fees) from 16 companies. The largest payer was Medtronic, Inc. with $1,650.
| Company | Payments | Amount |
|---|---|---|
| Medtronic, Inc. MDT | 18 | $1,650 |
| CeQur Corporation | 2 | $631 |
| Dexcom, Inc. DXCM | 5 | $196 |
| Corcept Therapeutics CORT | 10 | $174 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $78.83 |
| Lilly USA, LLC LLY | 4 | $67.19 |
| Novo Nordisk Inc NVO | 4 | $62.14 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $56.95 |
| Esperion Therapeutics, Inc. ESPR | 2 | $31.57 |
| Abbvie Inc. ABBV | 1 | $20.69 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.